CD Skripsi
Gambaran Pasien Yang Mendapatkan Targeted Therapy Pada Adenokarsinoma Paru Di Rsud Arifin Achmad Provinsi Riau Tahun 2015-2018
Lung Adenocarcinoma is a lung cancer that has a characteristic peripheral lesions with glandular formation. The incidence of adenocarcinoma is 40% of all lung cancer cases. Anti-cancer therapy that currently developing is targeted therapy. This therapy aims a specific targets, specific genes or certain proteins on the tumor cells. In Arifin Achmad regional hospital (RSUD Arifin Achmad) of Riau province, the usage of targeted therapy began from 2015, which is relatively new. This study aims to decide the description of patients who get targeted therapy in lung adenocarcinoma in Arifin achmad regional hospital of riau province in 2015-2018. This research is a retrospective descriptive study. The results showed that the characteristics of the lung Adenocarcinoma patients were mostly male (64.7%) and aged >40 years (90,6%). The number of lung adenocarcinoma patients with Epidermal Growth Factor Receptor (EGFR) gene mutation test was 89 patients out of 170 patients. Samples for the EGFR gene mutation test were widely extracted from pleural fluid (39,3%). lung adenocarcinoma patients with positive EGFR mutation test (31,5%) mostly had mutations in exon 19 (20,2%). The number of cases that given the targeted therapy in the form of EGFR-Tyrosin Kinase Inhibitor (EGFR- TKIs) were 25 people (89.3%) with the most type of EGFR-TKIs was gefitinib (16 people, 64%). The conclusion of this research is the location of EGFR mutation in lung adenocarcinoma found in exon 19 and gefitinib was the most widely administered type of targeted therapy.
Keyword: Lung adenocarcinoma, EGFR mutation, targeted therapy
Tidak tersedia versi lain